Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance

Warner K. Huh, Kevin A. Ault, David Chelmow, Diane D. Davey, Robert A. Goulart, Francisco A Garcia, Walter K. Kinney, L. Stewart Massad, Edward J. Mayeaux, Debbie Saslow, Mark Schiffman, Nicolas Wentzensen, Herschel W. Lawson, Mark H. Einstein

Research output: Contribution to journalArticle

197 Citations (Scopus)

Abstract

In 2011, the American Cancer Society, the American Society for Colposcopy and Cervical Pathology, and the American Society for Clinical Pathology updated screening guidelines for the early detection of cervical cancer and its precursors. Recommended screening strategies were cytology and cotesting (cytology in combination with hrHPV testing). These guidelines also addressed the use of hrHPV testing alone as a primary screening approach, which was not recommended for use at that time. There is now a growing body of evidence for screening with primary hrHPV testing, including a prospective US-based registration study. Thirteen experts including representatives from the Society of Gynecologic Oncology, American Society for Colposcopy and Cervical Pathology, American College of Obstetricians and Gynecologists, American Cancer Society, American Society of Cytopathology, College of American Pathologists, and the American Society for Clinical Pathology, convened to provide interim guidance for primary hrHPV screening. This guidance panel was specifically triggered by an application to the FDA for a currently marketed HPV test to be labeled for the additional indication of primary cervical cancer screening. Guidance was based on literature review and review of data from the FDA registration study, supplemented by expert opinion. This document aims to provide information for healthcare providers who are interested in primary hrHPV testing and an overview of the potential advantages and disadvantages of this strategy for screening as well as to highlight areas in need of further investigation.

Original languageEnglish (US)
Pages (from-to)178-182
Number of pages5
JournalGynecologic Oncology
Volume136
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Colposcopy
Early Detection of Cancer
Uterine Cervical Neoplasms
Cell Biology
Guidelines
Pathology
Expert Testimony
Health Personnel
Pathologists

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology
  • Medicine(all)

Cite this

Use of primary high-risk human papillomavirus testing for cervical cancer screening : Interim clinical guidance. / Huh, Warner K.; Ault, Kevin A.; Chelmow, David; Davey, Diane D.; Goulart, Robert A.; Garcia, Francisco A; Kinney, Walter K.; Massad, L. Stewart; Mayeaux, Edward J.; Saslow, Debbie; Schiffman, Mark; Wentzensen, Nicolas; Lawson, Herschel W.; Einstein, Mark H.

In: Gynecologic Oncology, Vol. 136, No. 2, 01.02.2015, p. 178-182.

Research output: Contribution to journalArticle

Huh, WK, Ault, KA, Chelmow, D, Davey, DD, Goulart, RA, Garcia, FA, Kinney, WK, Massad, LS, Mayeaux, EJ, Saslow, D, Schiffman, M, Wentzensen, N, Lawson, HW & Einstein, MH 2015, 'Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance', Gynecologic Oncology, vol. 136, no. 2, pp. 178-182. https://doi.org/10.1016/j.ygyno.2014.12.022
Huh, Warner K. ; Ault, Kevin A. ; Chelmow, David ; Davey, Diane D. ; Goulart, Robert A. ; Garcia, Francisco A ; Kinney, Walter K. ; Massad, L. Stewart ; Mayeaux, Edward J. ; Saslow, Debbie ; Schiffman, Mark ; Wentzensen, Nicolas ; Lawson, Herschel W. ; Einstein, Mark H. / Use of primary high-risk human papillomavirus testing for cervical cancer screening : Interim clinical guidance. In: Gynecologic Oncology. 2015 ; Vol. 136, No. 2. pp. 178-182.
@article{4477cfb7506546888b7f7f1030309268,
title = "Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance",
abstract = "In 2011, the American Cancer Society, the American Society for Colposcopy and Cervical Pathology, and the American Society for Clinical Pathology updated screening guidelines for the early detection of cervical cancer and its precursors. Recommended screening strategies were cytology and cotesting (cytology in combination with hrHPV testing). These guidelines also addressed the use of hrHPV testing alone as a primary screening approach, which was not recommended for use at that time. There is now a growing body of evidence for screening with primary hrHPV testing, including a prospective US-based registration study. Thirteen experts including representatives from the Society of Gynecologic Oncology, American Society for Colposcopy and Cervical Pathology, American College of Obstetricians and Gynecologists, American Cancer Society, American Society of Cytopathology, College of American Pathologists, and the American Society for Clinical Pathology, convened to provide interim guidance for primary hrHPV screening. This guidance panel was specifically triggered by an application to the FDA for a currently marketed HPV test to be labeled for the additional indication of primary cervical cancer screening. Guidance was based on literature review and review of data from the FDA registration study, supplemented by expert opinion. This document aims to provide information for healthcare providers who are interested in primary hrHPV testing and an overview of the potential advantages and disadvantages of this strategy for screening as well as to highlight areas in need of further investigation.",
author = "Huh, {Warner K.} and Ault, {Kevin A.} and David Chelmow and Davey, {Diane D.} and Goulart, {Robert A.} and Garcia, {Francisco A} and Kinney, {Walter K.} and Massad, {L. Stewart} and Mayeaux, {Edward J.} and Debbie Saslow and Mark Schiffman and Nicolas Wentzensen and Lawson, {Herschel W.} and Einstein, {Mark H.}",
year = "2015",
month = "2",
day = "1",
doi = "10.1016/j.ygyno.2014.12.022",
language = "English (US)",
volume = "136",
pages = "178--182",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Use of primary high-risk human papillomavirus testing for cervical cancer screening

T2 - Interim clinical guidance

AU - Huh, Warner K.

AU - Ault, Kevin A.

AU - Chelmow, David

AU - Davey, Diane D.

AU - Goulart, Robert A.

AU - Garcia, Francisco A

AU - Kinney, Walter K.

AU - Massad, L. Stewart

AU - Mayeaux, Edward J.

AU - Saslow, Debbie

AU - Schiffman, Mark

AU - Wentzensen, Nicolas

AU - Lawson, Herschel W.

AU - Einstein, Mark H.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - In 2011, the American Cancer Society, the American Society for Colposcopy and Cervical Pathology, and the American Society for Clinical Pathology updated screening guidelines for the early detection of cervical cancer and its precursors. Recommended screening strategies were cytology and cotesting (cytology in combination with hrHPV testing). These guidelines also addressed the use of hrHPV testing alone as a primary screening approach, which was not recommended for use at that time. There is now a growing body of evidence for screening with primary hrHPV testing, including a prospective US-based registration study. Thirteen experts including representatives from the Society of Gynecologic Oncology, American Society for Colposcopy and Cervical Pathology, American College of Obstetricians and Gynecologists, American Cancer Society, American Society of Cytopathology, College of American Pathologists, and the American Society for Clinical Pathology, convened to provide interim guidance for primary hrHPV screening. This guidance panel was specifically triggered by an application to the FDA for a currently marketed HPV test to be labeled for the additional indication of primary cervical cancer screening. Guidance was based on literature review and review of data from the FDA registration study, supplemented by expert opinion. This document aims to provide information for healthcare providers who are interested in primary hrHPV testing and an overview of the potential advantages and disadvantages of this strategy for screening as well as to highlight areas in need of further investigation.

AB - In 2011, the American Cancer Society, the American Society for Colposcopy and Cervical Pathology, and the American Society for Clinical Pathology updated screening guidelines for the early detection of cervical cancer and its precursors. Recommended screening strategies were cytology and cotesting (cytology in combination with hrHPV testing). These guidelines also addressed the use of hrHPV testing alone as a primary screening approach, which was not recommended for use at that time. There is now a growing body of evidence for screening with primary hrHPV testing, including a prospective US-based registration study. Thirteen experts including representatives from the Society of Gynecologic Oncology, American Society for Colposcopy and Cervical Pathology, American College of Obstetricians and Gynecologists, American Cancer Society, American Society of Cytopathology, College of American Pathologists, and the American Society for Clinical Pathology, convened to provide interim guidance for primary hrHPV screening. This guidance panel was specifically triggered by an application to the FDA for a currently marketed HPV test to be labeled for the additional indication of primary cervical cancer screening. Guidance was based on literature review and review of data from the FDA registration study, supplemented by expert opinion. This document aims to provide information for healthcare providers who are interested in primary hrHPV testing and an overview of the potential advantages and disadvantages of this strategy for screening as well as to highlight areas in need of further investigation.

UR - http://www.scopus.com/inward/record.url?scp=84923116935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923116935&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2014.12.022

DO - 10.1016/j.ygyno.2014.12.022

M3 - Article

C2 - 25579107

AN - SCOPUS:84923116935

VL - 136

SP - 178

EP - 182

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -